NASDAQ:GRCE Grace Therapeutics Q4 2025 Earnings Report $2.17 -0.02 (-0.68%) As of 10:47 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Grace Therapeutics EPS ResultsActual EPS-$0.21Consensus EPS -$0.23Beat/MissBeat by +$0.02One Year Ago EPSN/AGrace Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGrace Therapeutics Announcement DetailsQuarterQ4 2025Date6/20/2025TimeBefore Market OpensConference Call DateMonday, June 23, 2025Conference Call Time7:00AM ETUpcoming EarningsGrace Therapeutics' Q4 2026 earnings is estimated for Monday, June 22, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, June 23, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Grace Therapeutics Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCEMay 14 at 11:01 PM | prnewswire.comGrace Therapeutics (GRCE) price target decreased by 47.83% to 6.12April 28, 2026 | msn.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.May 15 at 1:00 AM | Weiss Ratings (Ad)FDA declines Grace's stroke drug over manufacturing and packaging issues, shares slumpApril 25, 2026 | msn.comGrace Therapeutics Shares Fall After FDA Flags Issues in Aneurysm Treatment ApplicationApril 23, 2026 | marketwatch.comFDA declines Grace's stroke drug over manufacturing and packaging issuesApril 23, 2026 | msn.comSee More Grace Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email. Email Address About Grace TherapeuticsGrace Therapeutics (NASDAQ:GRCE) (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease. The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways. Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.View Grace Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles YETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying OpportunityCisco’s Vertical Rally May Still Be in the Early InningsKarman: Defense Darling's Outlook Strengthens After 40% DropHow the 3 Leading Quantum Firms Stack Up After Q1 EarningsNebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive Run Upcoming Earnings Baidu (5/18/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
